500mg Fulvestrant in HR+ MBC

N/ACompletedNCT03708432

Fudan University100 enrolled

Overview

To study the real world use of 500mg Fulvestrant in HR+ MBC.

An observational, retrospective study of 500mg Fulvestrant in hormone receptor+/HER2- advanced breast cancer

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Breast Cancer

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Diagnosed with ER/PR+，HER2- advanced breast cancer 2. Advanced breast cancer included unresectable locally advanced breast cancer, de novo stage IV breast cancer, and recurrent metastatic breast cancer. 3.500mg Fulvestrant treatment of advanced breast cancer for at least one month, between Jan 2011 and Dec 2015. 4.Available medical history Exclusion Criteria: 1. Incomplete medical history 2. HER2 overexpression or gene amplification, ie, immunohistochemistry (IHC) 3+ or fluorescence in situ hybridisation (FISH)+, where appropriate.

Locations (1)

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, China

Outcomes

Primary Outcomes

PFS

Progression free survival

Time frame: 6 weeks

Secondary Outcomes

Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

Time frame: 6 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.